Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

New England Journal of Medicine

Volumn 345, Issue 6, 2001, Pages 398-407

  Albrecht, Mary A ^a,j   Bosch, Ronald J ^b   Hammer, Scott M ^c   Liou, Song Heng ^b   Kessler, Harold ^d   Para, Michael F ^e   Eron, Joseph ^f   Valdez, Hernan ^g   Dehlinger, Marjorie ^h   Katzenstein, Davida ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG MIXTURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT FAILURE; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MUTATION; NELFINAVIR; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; TREATMENT FAILURE; VIRAL LOAD;

EID: 0035833452     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200108093450602     Document Type: Article

References (24)

1. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
2. Report of the NIH Panel to define principles of therapy of HIV infection
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
8. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
9. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
10. Longer time to treatment failure and durability of response with efavirenz+ZDV+3TC: First analysis of full 1266 patient cohort from study 006
11. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
12. Virologic and CD4+ cell responses to new nucleoside regimens: Switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection
13. The effect of lamivudine in HIV infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine
14. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
15. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
16. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
17. Mutations in retroviral genes associated with drug resistance
18. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
19. A phase II, double-blind, placebo-controlled multicenter study to evaluate the effectiveness and tolerability of the combination of efavirenz (EFV, Sustiva, DMP-266) and indinavir (IDV) in HIV-1 infected patients receiving nucleoside analogue therapy (NRTI) at >36 weeks
20. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
21. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves short-term virological response
22. Phenotypic susceptibility and virologic responses in nucleoside reverse transcriptase inhibitor (NRTI)-experienced subjects receiving NRTIs + efavirenz (EFV), nelfinavir (NFV), or both in ACTG 364